**
Overview
Celiac disease (also spelled coeliac) is a lifelong, immune‑mediated condition in which the ingestion of gluten—a protein composite found in wheat, barley, rye, and related grains—provokes an abnormal immune response. This response targets the lining of the small intestine, specifically the villi, leading to villous atrophy, malabsorption of nutrients, and a cascade of inflammatory signals that can affect virtually any organ system. Clinical presentation is notoriously variable; some individuals experience classic gastrointestinal complaints such as chronic diarrhea, abdominal bloating, and weight loss, while others present with extra‑intestinal manifestations like anemia, osteoporosis, dermatitis herpetiformis, neurologic symptoms, or even infertility. Because the disease can be silent or atypical, many patients remain undiagnosed for years, increasing the risk of complications.Diagnosis hinges on a combination of serologic testing (anti‑tissue transglutaminase IgA, endomysial antibodies) and confirmatory duodenal biopsy demonstrating villous blunting. A strict, lifelong gluten‑free diet (GFD) is currently the only effective therapy, allowing intestinal healing and symptom resolution in most patients. However, adherence can be challenging due to hidden sources of gluten, cross‑contamination, and the social burden of dietary restriction. Ongoing research explores adjunctive therapies—such as enzyme supplements, tight junction modulators, and vaccines—but these remain experimental.
If you suspect you have celiac disease, consult a qualified healthcare professional for appropriate testing before initiating a gluten‑free diet, as premature dietary changes can interfere with diagnostic accuracy.
History/Background
The condition was first described in the 1st century CE by the Greek physician Aretaeus of Cappadocia, who noted a “coeliac affection” causing chronic diarrhea. Modern scientific understanding began in the mid‑20th century when Dutch pediatrician Dr. Willem‑Karel Dicke observed that wheat removal alleviated symptoms in children during World War II bread shortages, leading to the concept of a “gluten‑sensitive enteropathy.” In 1950, Dr. Margot Shiner performed the first intestinal biopsies confirming villous atrophy, establishing the histologic hallmark. The discovery of tissue transglutaminase (tTG) as the primary autoantigen in the 1990s revolutionized serologic screening, making large‑scale epidemiologic studies possible. By the early 2000s, prevalence estimates rose to about 1 % of many populations, revealing that celiac disease is far more common than previously thought.Key Information
- Pathophysiology: In genetically predisposed individuals (HLA‑DQ2 or HLA‑DQ8 haplotypes), gluten peptides resist digestion, cross the intestinal epithelium, and are deamidated by tTG, creating neo‑epitopes that trigger CD4⁺ T‑cell activation and autoantibody production. - Epidemiology: Affects roughly 1 % of the global population, with higher rates in individuals of European descent; many cases remain undiagnosed. - Symptoms: Can include chronic diarrhea, constipation, abdominal pain, bloating, weight loss, iron‑deficiency anemia, fatigue, osteoporosis, dermatitis herpetiformis, peripheral neuropathy, and reproductive issues. - Complications: Untreated disease raises the risk of refractory celiac disease, intestinal lymphoma (especially enteropathy‑associated T‑cell lymphoma), small‑bowel adenocarcinoma, and severe nutritional deficiencies. - Diagnosis: Requires positive serology (tTG‑IgA, EMA) plus duodenal biopsy showing Marsh III lesions; HLA typing may be used to exclude disease. - Management: Strict gluten‑free diet; periodic monitoring of serology, bone density, and nutritional status; multidisciplinary support (dietitians, gastroenterologists). - Research Frontiers: Enzyme therapy (e.g., ALV003), zonulin antagonists, peptide‑based vaccines (Nexvax2), and microbiome modulation are under investigation.Significance
Celiac disease exemplifies how a single dietary protein can trigger systemic autoimmunity, highlighting the intricate interplay between genetics, environment, and the gut immune system. Its high prevalence and often silent nature make it a public health concern; early detection prevents irreversible intestinal damage and reduces long‑term morbidity. The disease has spurred advances in immunology, genetics, and nutrition science, influencing guidelines for food labeling, restaurant practices, and patient advocacy worldwide. Moreover, the growing awareness of gluten‑related disorders has prompted the food industry to develop a wide array of certified gluten‑free products, improving quality of life for millions while also raising challenges related to cost, accessibility, and nutritional adequacy.INFOBOX:
- Name: Celiac Disease (Coeliac Disease)
- Type: Autoimmune Gastrointestinal Disorder
- Date: First modern description – 1950 (intestinal biopsy confirmation)
- Location: Worldwide (prevalence ~1 % of population)
- Known For: Immune‑mediated damage to small‑intestinal villi triggered by gluten ingestion
TAGS: celiac disease, gluten intolerance, autoimmune disorders, gastroenterology, nutrition, HLA genetics, gluten‑free diet, intestinal health
